- CDC
- Heart Failure
- Cardiovascular Clinical Consult
- Adult Immunization
- Hepatic Disease
- Rare Disorders
- Pediatric Immunization
- Implementing The Topcon Ocular Telehealth Platform
- Weight Management
- Screening
- Monkeypox
- Guidelines
- Men's Health
- Psychiatry
- Allergy
- Nutrition
- Women's Health
- Cardiology
- Substance Use
- Pediatrics
- Kidney Disease
- Genetics
- Complimentary & Alternative Medicine
- Dermatology
- Endocrinology
- Oral Medicine
- Otorhinolaryngologic Diseases
- Pain
- Gastrointestinal Disorders
- Geriatrics
- Infection
- Musculoskeletal Disorders
- Obesity
- Rheumatology
- Technology
- Cancer
- Nephrology
- Anemia
- Neurology
- Pulmonology
NIH COVID-19 Treatment Guidelines Updated Based on New Data
Treatment guidelines on COVID-19 from the NIH were updated today based on data from clinical trials of hydroxychloroquine, ivermectin, and IL-6 inhibitors.
The National Institutes of Health (NIH) on August 27, 2020, made updates to its recommendations on use of hydroxychloroquine/chloroquine, interleukin-6 inhibitors, and ivermectin in the treatment of patients infected with SARS-CoV2 virus. A new section was added on treatment considerations for children and adults with cancer who have COVID-19 and revisions were made to the section on pregnancy including on treatment for women during gestation.
The guidelines are updated as soon as published data and other authoritative information become available. Following are highlights of today's amendments.
